In Vitro Characterization of High Purity Factor IX Concentrates for the Treatment of Hemophilia B

Steven A Limentani; Kerry P Gowell; Steven R Deitcher

doi:10.1055/s-0038-1653825

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1995; 73(04): 584-591
DOI: 10.1055/s-0038-1653825

Original Articles

Clinical Studies

Schattauer GmbH Stuttgart

In Vitro Characterization of High Purity Factor IX Concentrates for the Treatment of Hemophilia B

Steven A Limentani

The Center for Hemostasis and Thrombosis Research, Division of Hematology and Oncology, Department of Medicine, New England Medical Center Hospitals and Tufts University School of Medicine, Boston, MA, USA

,

Kerry P Gowell

The Center for Hemostasis and Thrombosis Research, Division of Hematology and Oncology, Department of Medicine, New England Medical Center Hospitals and Tufts University School of Medicine, Boston, MA, USA

,

Steven R Deitcher

The Center for Hemostasis and Thrombosis Research, Division of Hematology and Oncology, Department of Medicine, New England Medical Center Hospitals and Tufts University School of Medicine, Boston, MA, USA

› Institutsangaben

Abstract

als PDF herunterladen

Summary

This study employed sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis and immunoblotting to assess the purity of seven high purity factor IX concentrates: Aimafix (Aima), AlphaNine-SD (Alpha Therapeutic), Factor IX VHP (Biotransfusion), Immunine (Immuno), Mononine (Armour Pharmaceutical), Nanotiv (Kabi Pharmacia), and 9MC (Blood Products Laboratory). The mean specific activity of these products ranged from 68 U factor IX/mg (Aimafix) to 246 U factor IX/mg (Mononine). SDS-PAGE analysis showed that the highest purity product, Mononine, had a single contaminating band under non-reducing conditions. Two additional bands were detected when this product was analyzed under reducing conditions. All other products had multiple contaminating bands that were more apparent under reducing than non-reducing conditions. The immunoblot for factor IX showed a dominant factor IX band for all products. In addition, visible light chain of factor IX was detected for AlphaNine-SD, Factor IX VHP, Immunine, Mononine, Nanotiv, and 9MC, suggesting that the factor IX in these products had undergone partial activation to factor IXa. Another contaminating band was visible at 49,500 for all of the products except 9MC. In addition to this band, high molecular weight contaminants were apparent for some products, most notably AlphaNine-SD. The identity of these bands is unknown. Immunoblotting failed to demonstrate factor VII as a contaminant of any of the high purity products, although factor Vila could be detected in some lots of Immunine, Nanotiv, and 9MC by a clot-based assay. Factor X contaminated Aimafix, AlphaNine-SD, Factor IX VHP, Immunine, Nanotiv, and 9MC, but activation products of factor X were not detected. Prothrombin contaminated all of the products except Mononine. Activation products of prothrombin were identified for three of four lots of Immunine and for one lot of Factor IX VHP. These results thus demonstrate that high purity factor IX concentrates differ substantially in the degree to which they are contaminated by potentially thrombogenic materials.

PDF (443 kb)

Referenzen

References
1 Pool JG, Shannon AE. Production of high-potency concentrates of antihemophilic globulin in a closed-bag system. NEJM 1965; 273: 1443
2 Tullis JL, Melin M, Jurigian P. Clinical use of human prothrombin complexes. NEJM 1965; 273: 667
3 Kasper CK. Clinical use of prothrombin complex concentrates: Report on thromboembolic complications. Thromb Diath Haemorrh 1975; 33: 640-644
4 Lusher JM. Thrombogenicity associated with factor IX complex concentrates. Sem Hematol 1991; 28 Suppl (Suppl. 06) 3-5
5 White II GC, Roberts HR, Kingdon HS, Lundblad RL. Prothrombin complex concentrates: Potentially thrombogenic materials and clues to the mechanism of thrombosis in vivo. Blood 1977; 49: 159
6 Seligsohn U, Kasper CK, Osterud B, Rapaport SI. Activated factor VII: Presence in factor IX concentrates and persistence in the circulation after infusion. Blood 1979; 53: 828
7 Giles AR, Nesheim ME, Hoogendoorn H, Tracy PB, Mann KG. The coagulant-active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (factor IX) concentrates in rabbits. Blood 1982; 59: 401
8 Kasper CK. Postoperative thrombosis in hemophilia B. NEJM 1973; 289: 160
9 Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Bottasso B, Simoni L, Rosenberg RD. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. Blood 1990; 76: 2540
10 Kim HC, Matts L, Eisele J, Czachur M, Saidi P. Monoclonal antibody- purified factor IXcomparative thrombogenicity to prothrombin complex concentrate. Sem Hematol 1991; 28 Suppl (Suppl. 06) 15
11 Kim HC, McMillan CW, White GC, Bergman GE, Horton MW, Saidi P. Purified factor IX using monoclonal immunoaffinity technique: Clinical trials in hemophilia B and comparison to prothrombin complex concentrates. Blood 1992; 79: 568
12 Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Santagostino E, Tradati FC, Rosenberg RD. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate. Br J Haematol 1991; 79: 606
13 Hampton KK, Preston FE, Lowe GD O, Walker ID, Sampson B. Reduced coagulation activation following infusion of a highly purified factor IX concentrate compared to a prothrombin complex concentrate. Br J Haematol 1993; 84: 279
14 Bemtorp E, Bjorkman S, Carlsson M, Lethagen S, Nilsson IM. Biochemical and in vivo properties of high purity factor IX concentrates. Thromb Haemost 1993; 70: 768
15 Limentani SA, Gowell KP. Evaluation of the purity and specific activity of two preparations of ultra-pure factor IX. Blood 1993; 82: 2369
16 Herring SW, Abildgaard C, Shitanishi KT, Harrison J, Gendler S, Heldebrant CM. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety. J Lab Clin Med 1993; 121: 394-405
17 Kasper CK, Abramson SB, Goldsmith JC, Herring S. In vivo recovery, halflife and safety of affinity purified solvent-detergent coagulation factor IX [Abstract]. Blood 1991; 78: 58 a
18 Bumouf T, Michalski C, Goudemand M, Huart JJ. Properties of a highly purified human plasma factor IX:c therapeutic concentrate prepared by conventional chromatography. Vox Sang 1989; 57: 225-232
19 Immunine product information. Immuno AG;
20 Hrinda ME, Huang C, Tarr GC, Weeks R, Feldman F, Schreiber AB. Preclinical studies of a monoclonal antibody-purified factor IX, MononineTM. Semin Hematol. 1991. 28 6-14
21 Löf A-L, Bemtorp E, Eriksson B, Mattson C, Svinhufvud L, Winge S, Östlin A. Characterization of a highly purified factor IX concentrate. In: Biotechnology of Blood Proteins. Rivat C, Stoltz J-F. eds Colloque INSERM/John Libbey Eurotext Ltd; 1993. pp 69-74
22 Feldman PA, Harris L, Evans DR, Evans HE. Preparation of a high purity factor IX concentrate using metal chelate affinity chromatography. In: Biotechnology of Blood Proteins. Rivat C, Stoltz J-F. eds Colloque INSERM/John Libbey Eurotext Ltd; 1993. pp 63-68
23 Fricke WA, Lamb MA. Viral safety of clotting factor concentrates. Semin Thromb Hemost 1993; 19: 54-61
24 Bradford M. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1977; 81: 485
25 Proctor RR, Rapaport SI. A partial thromboplastin time with kaolin: A simple screening test for first stage plasma clotting deficiencies. Am J Clin Pathol 1961; 36: 212
26 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 1970; 227: 680
27 Liebman HA, Limentani SA, Furie BC, Furie B. Immunoaffinity purification of factor IX (Christmas factor) by using conformation-specific antibodies directed against the factor IX-metal complex. Proc Natl Acad Sci USA 1985; 82: 3879
28 Farrugia A, Oates A, Spiers D, Young I, Herrington R. A microtitre plate test for assessment of in-vitro thrombogenicity in factor IX concentrates using a chromogenic substrate. Throm Res 1989; 53: 191
29 Liebman HA, Furie BC, Furie B. The factor IX phospholipid-binding site is required for calcium-dependent activation of factor IX by factor XIa. J Biol Chem 1987; 262: 7605
30 Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734
31 Hrinda ME, Huang C, Tarr GC, Weeks R, Feldman F, Schreiber AB. Preclinical studies of a monoclonal antibody-purified factor IX, Mononine. Sem Hematol 1991; 28 Suppl (Suppl. 06) 6
32 Seremetis SV, Aledort LM, Bergman GE, Bona R, Bray G, Brettler D, Eyster ME, Kessler C, Lau TS, Lusher J, Rickies F. Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: Effects on immune status. Lancet 1993; 342: 700
33 Hay CR, McEvoy P, Duggan-Keen M. Inhibition of lymphocyte IL2-receptor expression by factor VIII concentrate: A possible cause of immunosuppression in haemophiliacs. Br J Haematol 1990; 75: 278
34 Thorpe R, Dilger P, Dawson NJ, Barrowcliffe TW. Inhibition of interleukin-2 secretion by factor VIII concentrates: A possible cause of immunosuppression in haemophiliacs. Br J Haematol 1989; 71: 387
35 Cuthbert RJ, Ludlam CA, Steel CM, Beatson D, Peutherer JR. Immunological studies in HIV seronegative haemophiliacs: Relationships to blood product therapy. Br J Haematol 1992; 80: 364
36 Soria AG, Bouzas MB, Anselmo A, Ruibal-Ares BH. Modulation of allogeneic cytotoxic activity by factor VIII or IX concentrates. Haematologica 1991; 76: 33